NextGen Pathology Selects Proscia to Establish AI Foundation for Business Growth
NextGen Pathology has selected Proscia's Concentriq platform to establish an AI foundation that will support the pathology group's business expansion efforts. The adoption of Proscia's artificial intelligence platform is specifically designed to position NextGen Pathology as a strategic partner for biopharmaceutical research organizations. Proscia's Concentriq platform provides AI-powered digital pathology capabilities that enable automated image analysis and workflow optimization for pathology laboratories. By implementing this technology infrastructure, NextGen Pathology aims to enhance its computational pathology services and expand its capacity to support drug discovery and development processes for pharmaceutical companies.
Why It Matters
This partnership represents the growing adoption of AI-powered digital pathology platforms in clinical and research settings. As pharmaceutical companies increasingly rely on computational pathology for drug development, pathology service providers must invest in AI infrastructure to remain competitive and meet the technical demands of biopharmaceutical research partnerships.
This summary is generated using AI analysis of the original press release. Always refer to the original source for complete details.